AbbVie wins FDA approval for first outpatient blood cancer ADC
AbbVie's Decnupaz received FDA approval May 27 for ultra-rare BPDCN, replacing the only prior therapy that required inpatient monitoring, opening access to a disease affecting ~500–1,000 U.S. patients yearly.
Neomorph Closes $100M Series B With First Patient Dosed
Neomorph raised $100M in Series B funding to advance NEO-811, a molecular glue degrader with a first-in-human patient already dosed in Phase 1/2 trials for renal cancer, backed by Deerfield Management and pharma giants Novo Nordisk, Biogen, and AbbVie.